Vaxart's Future on the Ballot: Boardroom Battle Rages Over Oral Vaccine Firm

SOUTH SAN FRANCISCO, Calif. – June 26, 2026 – Clinical-stage biotechnology firm Vaxart, Inc. finds itself at a critical juncture, not in the laboratory, but in the boardroom. As the company pushes its revolutionary oral pill-based vaccines through late-stage trials, a contentious proxy battle with a dissident shareholder group threatens to reshape its leadership and strategic direction. With an Annual Meeting of Stockholders looming on July 16, both sides are making their final appeals, leaving investors to decide who is best equipped to steer the company through its most pivotal phase.

In its latest move, Vaxart published a detailed presentation urging shareholders to vote for its six director nominees on the WHITE proxy card, framing the contest as a choice between seasoned expertise and unacceptable risk. The company is developing what could be a paradigm shift in vaccination—pills that can be shipped and stored without refrigeration—targeting high-value markets like COVID-19, norovirus, and influenza. However, this scientific promise is now shadowed by a conflict over corporate governance, financial performance, and the fundamental vision for the company's future.

A Tale of Two Visions

At the heart of the dispute are two starkly different narratives. Vaxart’s current board, led by CEO Steven Lo, presents itself as a purpose-built team with deep expertise in vaccine development, clinical trials, and regulatory affairs. They argue they have skillfully navigated an industry rocked by post-pandemic funding shifts and regulatory hurdles. The board points to key achievements, including securing the continuation of funding from the U.S. Biomedical Advanced Research and Development Authority (BARDA) for its lead COVID-19 program and executing a $25 million share purchase agreement to provide flexible access to capital.

"The Board is purpose-built to guide Vaxart through its next phase of value creation," the company stated in its release, emphasizing its role in advancing a pipeline that includes a fully enrolled Phase 2b COVID-19 trial. The management team argues that its disciplined strategy prioritizes programs with the strongest scientific and commercial potential, positioning the company for significant value creation milestones, including a full efficacy readout from its main COVID-19 trial cohort expected in early 2027.

In sharp contrast, the dissident shareholder group, which calls itself “Concerned Vaxart Stockholders,” paints a picture of staggering value destruction and a board that is deaf to investor concerns. Led by personal injury lawyer Daniel P. Houle, the group holds a collective stake of approximately 0.7% and highlights a 91% decline in Vaxart's share price since 2020 and cumulative losses of around $343 million over the same period. They criticize executive compensation and shareholder dilution while pointing to a history of governance clashes. At the 2025 Annual Meeting, for instance, shareholders rejected a proposed reverse stock split with 59.1% voting against it, and four of the six incumbent directors, including CEO Steven Lo, failed to receive majority support yet retained their seats under a plurality voting standard.

Leadership Under the Microscope

The proxy contest has intensified scrutiny on the qualifications of the leaders vying for control. Vaxart champions its slate of six nominees, which includes two independent directors added in the last 18 months as part of a board refreshment effort. The company highlights the credentials of individuals like Dr. James B. Breitmeyer, who brings over 35 years of clinical development and vaccine experience, as essential for overseeing complex clinical and regulatory pathways.

Conversely, Vaxart has launched a blistering critique of the dissident nominees, stating they "lack relevant clinical-stage biotech expertise, misrepresented their qualifications and offered no credible ideas for value creation." The company has publicly identified the dissident nominees' professions—Mr. Houle as a personal injury lawyer, Dr. Mark Silverberg as an executive at a private surrogacy agency, and Dr. Matthew M. Wallace as a dermatologic surgeon—to argue they are ill-equipped to govern a public biotech firm. Vaxart also claims it has made multiple settlement offers, but that Mr. Houle is waging a "self-interested campaign primarily focused on ‘winning’ a Board seat for himself."

The dissident group counters that their campaign is about installing independent, stockholder-aligned directors who will demand accountability. They frame their push as giving a voice to retail investors who have watched their investment diminish. Their argument suggests that industry experience is less important than a genuine commitment to shareholder interests, which they claim the current board has failed to demonstrate.

Innovation in the Balance

Beyond the boardroom drama, the future of a promising technology platform hangs in the balance. Vaxart's oral vaccines could eliminate the need for needles and cold-chain logistics, a significant advantage for global distribution and patient compliance. The company’s lead candidate, an oral pill vaccine for COVID-19, is deep into a Phase 2b study supported by BARDA. This trial has fully enrolled approximately 5,400 participants, and Vaxart expects to release 12-month safety data from a 400-person sentinel cohort in the coming weeks, with the primary efficacy data from the larger cohort to follow in early 2027.

The relationship with BARDA itself illustrates the challenging landscape Vaxart's management has navigated. After an industry-wide stop-work order in early 2025, Vaxart successfully negotiated the continuation of its funding. However, the program later faced a partial termination in August 2025, reducing the trial's participant size by roughly half and the available funding, which now stands at approximately $345 million. The board presents its ability to maintain this crucial government partnership as a testament to its leadership, while critics might see the funding reduction as a sign of wavering confidence. The outcome of the proxy vote could determine the leadership team that oversees these final, critical trial stages and any subsequent regulatory submissions.

A Broader Trend in Biotech

Vaxart’s situation is emblematic of a wider trend of shareholder activism in the high-risk, high-reward biotechnology sector. Clinical-stage companies are often targets due to long development timelines, high cash burn, and volatile stock prices, which can create frustration among investors. Campaigns led by groups with small ownership stakes, like the Houle group's 0.7% holding, often focus on governance failures as a lever to enact change.

Despite the dissidents' claims of financial mismanagement, Vaxart's recent financial disclosures show a company managing its resources in a difficult market. As of the first quarter of 2026, the company held approximately $61 million in cash, projecting a runway into the second quarter of 2027, bolstered by a 21% workforce reduction in 2025. While the long-term stock performance is poor, shares have surged over 80% year-to-date, suggesting some renewed investor optimism ahead of key clinical data. As the July 16 meeting approaches, shareholders must weigh the current board’s scientific and regulatory experience against the dissidents' call for greater accountability, a decision that will undoubtedly shape the next chapter for Vaxart and its innovative oral vaccine platform.